Overview
Overview
Nephrogenic progenitor cells differentiated from UCT-WJ-MSCs; supporting repair of renal tubular and glomerular structures and modulating renal inflammation and fibrosis
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| Derived from P2 UCT-WJ-MSCs via intermediate mesoderm induction |
| BMP-4 Activin-A → WT1/PAX2 positive metanephric mesenchyme specification |
| DMSO-free cryopreservation |
| Post-thaw viability 95% |
| Markers: WT1⁺, PAX2⁺, CD24⁺ (renal progenitor), CD133⁺, SIX2⁺ |
| HGF secretion confirmed by ELISA prior to release |
Clinical Overview
Clinical Overview
Chronic kidney disease (CKD) affects approximately 850 million people globally and is characterized by progressive nephron loss, glomerular and tubular fibrosis, and inflammatory damage — all without approved regenerative therapies. Akira Kidney Progenitor Cells derived from UCT-WJ-MSCs provide a nephrogenic cell population capable of homing to damaged renal tissue (via SDF-1/CXCR4 and injury chemokines), engrafting in tubular and glomerular structures, and secreting a potent renoprotective secretome.[1] HGF — the primary paracrine driver — activates Met receptor on tubular epithelial cells, promoting tubulogenesis, anti-apoptosis (PI3K/Akt), and MMP-dependent fibrosis resolution. The cells also suppress the key drivers of CKD progression: TGF-β1-mediated fibrosis, complement activation, and inflammatory cytokine production.
Process
Mechanism of Action
Renal Progenitor Niche Engraftment: WT1+/PAX2+ progenitors integrate into Bowman's capsule epithelium and tubular walls via CD44 and CD133 niche interactions, self-renewing locally to maintain a progenitor pool for ongoing nephron repair.
HGF/Met-Driven Tubulogenesis: HGF secretion activates Met on proximal tubular cells, driving tubular regeneration via PI3K/Akt anti-apoptotic signaling, MAPK/ERK-driven proliferation, and Wnt7b-mediated tubulogenesis — restoring tubular architecture in AKI and CKD.
Anti-Fibrotic Mechanism: TGF-β1 suppression via decorin, HGF antagonism, and miR-21 modulation (paradoxically anti-fibrotic in renal context) prevents fibroblast-to-myofibroblast transition, preserving GFR and reducing CKD progression rate.
Immunomodulation: IL-10, PGE2, and IDO secretion suppresses resident macrophage and dendritic cell activation in the glomerular and interstitial compartments — reducing inflammatory nephritis and complement-mediated injury.
Vascular Support: VEGF and Ang-1 secretion promotes glomerular capillary repair and restores filtration surface area in patients with proliferative nephritis or diabetic nephropathy-associated microangiopathy.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| WT1 / PAX2 | Nephrogenic transcription factors; renal progenitor identity |
| CD133 / CD24 | Renal progenitor surface markers; clonogenic capacity |
| HGF (Hepatocyte Growth Factor) | Primary renoprotective paracrine factor; tubulogenesis, anti-fibrotic |
| VEGF-A / Ang-1 | Glomerular and peritubular capillary maintenance |
| miR-21 / TGF-β modulators | Anti-fibrotic regulation preventing CKD progression |
| IL-10 / IDO / PGE2 | Immunosuppression of glomerulonephritis and interstitial nephritis |
| SDF-1 (CXCL12) | Injury site homing signal gradient in damaged kidney |
| Decorin | TGF-β sequestering proteoglycan; anti-fibrotic extracellular matrix modulator |
Applications
Therapeutic Applications
- Acute Kidney Injury (AKI) — tubular repair, GFR restoration, dialysis prevention
- Chronic Kidney Disease (CKD Stages 2–4) — progression slowing, nephron preservation
- Diabetic Nephropathy — glomerular protection, proteinuria reduction
- IgA Nephropathy / Glomerulonephritis — immunomodulation, podocyte protection
- Transplant Nephritis — tolerance induction, delayed graft function mitigation
- Nephrotic Syndrome — podocyte stabilization, proteinuria reduction
- Lupus Nephritis — combined with UCT-MSC infusion for autoimmune renal protection
- CKD-associated Anemia — through erythropoietin support and renal parenchyma preservation
Evidence
Clinical & Preclinical Evidence
In cisplatin-induced AKI models, IV injection of UCT-MSC-derived renal progenitors at 24h post-injury reduced serum creatinine by 55% at day 5, prevented tubular necrosis (proximal tubule injury score 1.2 vs 3.8 in control), and improved 14-day survival from 40% to 85% — confirming potent renoprotective efficacy.
In diabetic nephropathy models (STZ-induced), UCT-MSC-derived renal progenitors administered every 4 weeks over 16 weeks reduced 24h urinary albumin from 310μg to 85μg, preserved podocyte density (podocin expression maintained), and reduced mesangial expansion score by 60%.
In IRI (ischemia-reperfusion injury) kidney models, UCT-MSC-derived renal progenitor secretome reduced TGF-β1 expression by 70%, reduced fibronectin deposition by 65%, and preserved proximal tubule brush border integrity (assessed by LTL staining) vs IRI control — confirming anti-fibrotic and structural preservation.
For transplant nephritis, MSC infusions (including UCT-derived) in Phase I/II trials have consistently demonstrated tolerance induction and reduction of donor-specific antibodies, supporting their role in transplant nephropathy prevention.
The 2023 review of MSC bench-to-bedside translation (PMC12344367) confirms MSC-mediated renoprotection through mitochondrial transfer to injured tubular cells, HGF/Met signaling, and macrophage M2 polarization — all mechanisms active in Akira Kidney Progenitor Cells.[2]